Darolutamide in aggiunta all'ADT rispetto all'ADT nel carcinoma prostatico sensibile agli ormoni metastatico (ARANOTE)
Uno studio di fase 3 randomizzato, in doppio cieco, controllato con placebo su darolutamide in aggiunta alla terapia di privazione degli androgeni (ADT) rispetto al placebo più ADT negli uomini con carcinoma prostatico metastatico sensibile agli ormoni (mHSPC)
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Kingswood, New South Wales, Australia, 2747
- Nepean Hospital
-
St Leonards, New South Wales, Australia, 2065
- Northern Cancer Institute
-
Sydney, New South Wales, Australia, 2109
- Macquarie University Hospital - Oncology Department
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Cancer Research South Australia
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
- Peninsula Oncology Centre
-
Heidelberg, Victoria, Australia, 3084
- Austin Health
-
-
-
-
-
Rio de Janeiro, Brasile, 22793-080
- Instituto COI de Educação e Pesquisa
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasile, 41950-640
- Assistência Multidisciplinar em Oncologia (AMO)
-
-
Goiás
-
Goiânia, Goiás, Brasile, 74605-070
- Hosp. Araujo Jorge da Associação de Combate ao Câncer
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasile, 30130-100
- Hospital da Universidade Federal de Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasile, 30150-270
- Cetus Oncologia Hospital Dia
-
-
Paraná
-
Curitiba, Paraná, Brasile, 81520-060
- Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasile, 59040-000
- Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
-
-
Rio Grande do Sul
-
Pelotas, Rio Grande do Sul, Brasile, 96020-080
- Unidade de Pesquisas Clinicas em Oncologia
-
Porto Alegre, Rio Grande do Sul, Brasile, 90850-170
- Hospital Mae de Deus
-
Porto Alegre, Rio Grande do Sul, Brasile, 91350-280
- FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
-
Porto Alegre, Rio Grande do Sul, Brasile, 90020-090
- Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
-
-
São Paulo
-
Barretos/SP, São Paulo, Brasile, 14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
São José do Rio Preto, São Paulo, Brasile, 15090-000
- Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
-
São Paulo, São Paulo, Brasile, 03102-002
- IBCC - Instituto Brasileiro de Controle do Cancer
-
São Paulo, São Paulo, Brasile, 01243-020
- Urobrasil
-
São Paulo, São Paulo, Brasile, 04039-004
- Inst. de Assistência Médica ao Sérvidor Público Estadual
-
-
-
-
Ontario
-
Burlington, Ontario, Canada, L7N 3V2
- G. Kenneth Jansz Medicine Professional Corporation
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
-
-
-
-
-
Santiago, Chile, 7510032
- Oncovida
-
Santiago, Chile
- UROMED
-
Santiago, Chile, TBC
- Hospital Clínico de la Pontificia Univ. Católica de Chile
-
Santiago, Chile, 7500921
- Fundación Arturo López Perez
-
-
Araucania
-
Temuco, Araucania, Chile, 4781156
- Centro de Investigación Clínica del Sur
-
-
Santiago Metropolitan
-
Providencia, Santiago Metropolitan, Chile, 7500653
- Centro de Estudios Clínicos SAGA SpA
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- OncoCentro
-
-
-
-
-
Beijing, Cina, 100142
- Beijing Cancer Hospital
-
Beijing, Cina, 100083
- Peking University Third Hospital
-
Beijing, Cina, 100000
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Anhui
-
Hefei City, Anhui Province, Anhui, Cina, 230031
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100730
- Beijing Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510000
- Sun Yat-sen University Cancer Center
-
Guangzhou, Guangdong, Cina, 510180
- Guangzhou First People Hospital
-
Shenzhen, Guangdong, Cina, 518172
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
-
Hubei
-
Wuhan, Hubei, Cina, 430030
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
Wuhan, Hubei, Cina, 430079
- Hubei Cancer Hospital
-
Wuhan, Hubei, Cina, 430071
- Zhongnan hospital ,Wuhan University
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- Hunan Cancer Hospital - Oncology Department
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210008
- NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
-
Nantong, Jiangsu, Cina, 226361
- Nantong tumor hospital
-
Suzhou, Jiangsu, Cina, 215004
- The 2nd Affiliated Hospital of Soochow University
-
-
Jilin
-
Changchun, Jilin, Cina, 130021
- 1st Hospital of Jilin University
-
-
Liaoning
-
Shengyang, Liaoning, Cina, 110042
- Liaoning Cancer Hospital and Institute
-
-
Shandong
-
Yantai, Shandong, Cina, 264000
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Xi’an, Shanxi, Cina, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610072
- SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
-
Chengdu, Sichuan, Cina, MISSING
- Sichuan University West China Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310000
- The 1st Affiliated Hospital of Zhejiang University
-
Hangzhou, Zhejiang, Cina, 310014
- ZheJiang Provincial People's Hospital
-
Ningbo, Zhejiang, Cina, 315010
- Ningbo First Hospital
-
Wenzhou, Zhejiang, Cina, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Chandigarh, India, 160012
- Post Graduate Institute of Medical Education and Research
-
Kolkata, India, 700156
- Tata Medical Center
-
Nashik, India, 422009
- Apex Wellness Hospital
-
New Delhi, India, 110 085
- Rajiv Gandhi Cancer Institute & Research Centre
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530017
- Mahatma Gandhi Cancer Hospital & Research Institute
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380016
- The Gujarat Cancer & Research Institute
-
Ahmedabad, Gujarat, India, 380060
- HCG Cancer Centre - Ahmedabad
-
Vadodara, Gujarat, India, 390007
- Cancer Care Clinic - Vadodara
-
-
Karnataka
-
Belagavi, Karnataka, India, 590010
- K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
-
Bengaluru, Karnataka, India, 560027
- Healthcare Global Enterprises Ltd
-
-
Kerala
-
Kochi, Kerala, India, 682 041
- Amrita Institute of Medical Sciences
-
Thiruvananthapuram, Kerala, India, 695011
- Regional Cancer Centre - Thiruvananthapuram
-
-
Maharashtra
-
Chhatrapati Sambhajinagar, Maharashtra, India, 431001
- Marathwada Regional Cancer Centre and Research Institute
-
Mumbai, Maharashtra, India, 400026
- Jaslok Hospital and Research Centre
-
Nashik, Maharashtra, India, 422004
- Curie Manavata Cancer Centre
-
Pune, Maharashtra, India, 411001
- Jehangir Hospital
-
-
Odisha
-
Bhubaneswar, Odisha, India, 751019
- All India Institute of Medical Sciences
-
Bhubaneswar, Odisha, India, 751007
- Sparsh Hospital & Critical Care
-
-
Puducherry
-
Gorimedu, Puducherry, India, 605006
- Jawaharlal Institute Of Postgraduate Medical Education and R
-
-
Punjab
-
Ludhiana, Punjab, India, 141008
- Christian Medical Center & Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302017
- Sawami Man Singh (SMS) Medical College & Attached Hospitals
-
-
Tamil Nadu
-
Madurai, Tamil Nadu, India, 625020
- Apollo Speciality Hospitals
-
Madurai, Tamil Nadu, India, 625107
- Meenakshi Mission Hospital & Research Centre
-
-
-
-
-
Daugavpils, Lettonia, LV-5417
- Daugavpils Regional Hospital
-
Riga, Lettonia, 1038
- RAKUS Hospital Gailezers
-
Riga, Lettonia, LV-1001
- URO Ltd.
-
Riga, Lettonia, LV-1002
- P. Stradins Clinical University Hospital
-
Valmiera, Lettonia, LV-4201
- Vidzemes Hospital
-
-
-
-
-
Kaunas, Lituania, LT-50009
- The Hospital of Lithuanian University of Health SciencesLUHS
-
Klaipėda, Lituania, LT-92288
- PI Klaipedos University Hospital
-
Vilnius, Lituania, LT-08660
- National Cancer Institute
-
Vilnius, Lituania, LT-08661
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
Bay of Plenty
-
Tauranga, Bay of Plenty, Nuova Zelanda, 3112
- Tauranga Urology Research Limited
-
-
Canterbury
-
Christchurch, Canterbury, Nuova Zelanda, 8013
- Canterbury Urology Research Trust
-
-
Waikato Region
-
Hamilton, Waikato Region, Nuova Zelanda, 3240
- Waikato Hospital
-
-
-
-
-
Lima, Perù, LIMA 11
- Hospital Militar Luis Arias Schreiber
-
Lima, Perù, LIMA 27
- Clínica El Golf
-
-
Lima region
-
San Isidro, Lima region, Perù, 15036
- Aliada
-
Santiago de Surco, Lima region, Perù, 15033
- Hospital Guillermo Almenara Irigoyen
-
-
-
-
-
Arkhangelsk, Russia, 163045
- Arkhangelsk Clinical Oncology Dispensary
-
Chelyabinsk, Russia, 454087
- Chelyabinsk Regional Oncology Dispensary
-
Chelyabinsk, Russia, 454048
- Ltd "EVIMED"
-
Ivanovo, Russia, 153040
- Ivanovo Regional Oncology Dispensary
-
Kazan', Russia, 420029
- Republican Clinical Oncology Dispensary Kazan
-
Moscow, Russia, 117997
- Research Centre of X-ray and Radiology
-
Nizhny Novgorod, Russia, 603109
- Volga District Med Center FMBA
-
Novosibirsk, Russia, 630099
- LLC Reafan
-
Novosibirsk, Russia, 630099
- Medical Center "Avicenna"
-
Omsk, Russia, 644013
- Clinical Oncological Dispensary of Omsk Region
-
Saint Petersburg, Russia, 196006
- AV Medical Group
-
Saint Petersburg, Russia, 197758
- Russian Scientific Radiology and Surgery Technologies Center
-
Saint Petersburg, Russia, 197758
- Scientific Research Instutute of Oncology n.a. N.N. Petrov
-
Tyumen, Russia, 625041
- Multi-Field Clinical Medical Center "Medical City"
-
Ufa, Russia, 450054
- Republican Clinical Oncology Dispensary
-
Vologda, Russia, 160022
- Vologda Regional Hospital
-
Yekaterinburg, Russia, 620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
-
Barcelona, Spagna, 08025
- Fundacio Puigvert | Urologia
-
Barcelona, Spagna, 08208
- Parc Tauli Hospital Universitari | Oncologia
-
Cáceres, Spagna, 10003
- Hospital San Pedro De Alcantara | Oncologia
-
Málaga, Spagna, 20910
- Hospital Universitario Virgen De La Victoria | Urologia
-
Seville, Spagna, 41013
- Hospital Universitario Virgen Del Rocio S.L. | Urologia
-
-
Madrid
-
Alcorcón, Madrid, Spagna, 28922
- Hospital Universitario Fundacion Alcorcon | Urologia
-
-
-
-
-
Cape Town, Sud Africa, 7570
- Cape Town Oncology Trials
-
-
Eastern Cape
-
Port Elizabeth, Eastern Cape, Sud Africa, 6045
- Cancercare Langenhoven
-
-
Gauteng
-
Johannesburg, Gauteng, Sud Africa, 1475
- East Rand Medical Research Unit
-
Pretoria, Gauteng, Sud Africa, 2
- University of Pretoria, Clinical Research Unit
-
-
-
-
-
Changhua, Taiwan, 50006
- Changhua Christian Hospital
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
-
Kaohsiung
-
Kaohsiung City, Kaohsiung, Taiwan, 807377
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
-
-
-
Cherkasy, Ucraina, 18009
- CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
-
Dnipro, Ucraina, 49102
- City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
-
Kyiv, Ucraina, 4107
- Kyiv Regional Oncological Dispensary
-
Kyiv, Ucraina, 02660
- Kyiv City Hospital #3 - Department of Urology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of prostate
- Metastatic disease
- Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
- Treatment with radiotherapy within 2 weeks before randomization
- Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
- Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
- Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
- A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
- Inability to swallow oral medications
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Darolutamide+ADT
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy |
Coated tablet, oral administration Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy |
|
Comparatore placebo: Placebo+ADT
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy |
Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy Coated tablet matching Darolutamide in appearance, oral administration |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Radiological Progression-free Survival (rPFS) Assessed by Central Review
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: From randomization to the final analysis date, approximately 47 months
|
Time from the date of randomization to the date of death from any cause. |
From randomization to the final analysis date, approximately 47 months
|
|
Time to Castration-Resistant Prostate Cancer (CRPC)
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first). |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Initiation of Subsequent Anti-cancer Therapy
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to PSA Progression
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
PSA Undetectable Rates (<0.2 ng/mL)
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Pain Progression
Lasso di tempo: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Number of Participants With Adverse Events as a Measure of Safety
Lasso di tempo: From start of study drug administration until 30 days after the last administration
|
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug. |
From start of study drug administration until 30 days after the last administration
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16.
- Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.07.026. Online ahead of print.
- Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 May;27(5):614-624. doi: 10.1016/S1470-2045(26)00014-8. Epub 2026 Apr 9.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Neoplasie genitali, maschio
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie genitali, maschio
- Malattie della prostata
- Malattie urogenitali maschili
- Neoplasie prostatiche
- Effetti fisiologici dei farmaci
- Ormoni, sostituti ormonali e antagonisti ormonali
- Antagonisti ormonali
- Azioni farmacologiche
- Azioni e usi chimici
- Antagonisti degli androgeni
- Daroutamide
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 21140
- 2020-003093-48 (Numero EudraCT)
- 2022-502244-12-00 (Altro identificatore: CTIS (EU))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .